Table 1.
Features of eight published models that prognosticate breast cancer outcomes
| First author; publication year | Clinical subtype | Training data (n) | Validation data (n) | Gene signature |
|---|---|---|---|---|
| Teschendorff et al25 2007 | ER− | 713 | 343 | 7-gene panel: C1QA, IGIC2, LY9, TNFRSF17, SPP1, XCL2, HLA-F |
| Teschendorff et al26 2010 | All | 1,223 | 830 | IL2, IL12, IFNG, IL4, IL13, TGFβ |
| Oh et al27 2012 | LN− | 684 | 616 | UBE2C, PRC1, CCNB2, CDC20, CD3D, CD52, CCL19, TRBV20-1 |
| Bianchini et al28 2010 | ER+, HER2−, HER2+ | 684 | 233 | 15-gene panel: LYN, STK17A, CSF1R, PIM2, LCK, STK17B, BTK, HCK, PRKCB1, PRKCQ, FYN, ITK, ZAP70, MAP4K1, STK10 |
| Nagalla et al29 2013 | All | 977 | 977 | B/P metagenes, M/D metagenes, T/NK metagenes |
| Yau et al30 2010 | ER− | 199 | 75 | 14-gene panel: RG54, CXCL13, HAPLN1, HRBL, MATN1, PRTN3, SSX3, RPS28, EXOC7, ABO, CLIC5, RFXDC2, ZNF3, PRRG3 |
| Ursini-Siegel et al31 2010 | HER2+, basal | 179 | 2,481 | 43-gene SRISa: CD247, CD3E, CD4, CD28, CTLA4, CXCL11, CXCL13, CXCL9, CXCR3, HLA-DQA1, IL1B, ITK, LAG3, LCK, NFATC2, PPIA, PTPRC, SLAMF6, SLAMF7, SLAMF9, TCRA, RELT, CD27, VTCN1, ATRN, CD69, ICOS, IL7R, B2M, CD8B, GZMB, IFNG, IL12B, LILRB3, TIA1, CD72, IGHG1, IGHM, IGHG2, IGJ, IL4, C1S, C3 |
| Cheng et al32 2013 | ER− | 1,981 | 184 | Lymphocyte-specific immune recruitment panel: PTPRC, CD53, LCP2, LAPTM5, DOCK2, IL10RA, CYBB, CD48, ITGB2, EVI2B |
Notes:
a
43 gene ShcA-regulated immune signature (SRIS). See supplementary material for additional information.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor 2; LN, lymph node.